Tirzepatide vs Semaglutide: Comparing All 5 GLP-1 Medications (2026)

The short version: tirzepatide won on weight loss.

Not by a little.

In SURMOUNT-5, the trial that finally put both drugs head-to-head at maximum doses for weight management, tirzepatide patients shed 20.2% of body weight over 72 weeks. Semaglutide patients lost 13.7%. That gap held up across 751 participants. It wasn't a fluke.

Side effects? Roughly a draw.

Both are weekly injections. Both make people nauseous at first. Neither is dramatically more tolerable than the other, and that's not a cop-out answer. The clinical data genuinely doesn't separate them cleanly on tolerability.

So what actually decides the choice?

Your diagnosis. What your doctor thinks fits your history. And whether the drug is even available where you live.

So this article covers all five. Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda.

Trial numbers, mechanism differences, what's actually stocked in the UAE, and a practical framework for the conversation with your doctor. Sources: FDA prescribing information, trial publications, peer-reviewed literature, nothing invented. Mounjaro (tirzepatide) KwikPen options are stocked at MedX Pharmacy. Valid prescription required for all.

How These Medications Work: GLP-1 vs Dual GIP/GLP-1

One receptor. Two receptors. That's the gap.

Here's what GLP-1 actually does in your body.

After a meal, your gut releases GLP-1 (glucagon-like peptide-1).

Insulin goes up. Glucagon backs off. Digestion slows. Food lingers longer in the stomach. The brain gets a fullness signal.

Semaglutide replicates that whole cascade without the meal.

It's the molecule inside both Ozempic and Wegovy. Same compound, different brands, different FDA-approved uses and dose ceilings. We'll get to that.

Tirzepatide adds GIP to the mix.

GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone, earlier in the digestion timeline than GLP-1.

Why does hitting both produce better weight loss? Honestly, the mechanism isn't fully settled.

The pharmacologists have working theories: enhanced insulin secretion, amplified satiety signals, something happening at the fat metabolism level. Nothing fully proven yet. What is proven: tirzepatide outperforms semaglutide on weight loss in every head-to-head trial published so far. That consistency is the evidence, whatever the mechanism turns out to be. It's the molecule in both Mounjaro and Zepbound. Mounjaro FDA prescribing information has the full technical detail.

The Complete GLP-1 Comparison Table

Sorting through ozempic vs wegovy while also trying to understand where Saxenda fits? The table below covers it.

All five medications, side by side. Drug class, approved indication, dosing schedule, trial weight loss, manufacturer. More context at the drugs.com GLP-1 comparison.

Quick clarifications: Ozempic has no FDA weight loss approval. Wegovy is the weight management semaglutide. Mounjaro is type 2 diabetes only; Zepbound is the weight management tirzepatide.

Weight Loss Results: Semaglutide vs Tirzepatide Weight Loss in Clinical Trials

SURPASS-2 landed first. Direct matchup in type 2 diabetes patients.

Tirzepatide at 15mg: HbA1c down 2.30 percentage points.

Semaglutide 1mg: down 1.86.

Weight loss followed the same spread. Tirzepatide beat semaglutide at 5mg, 10mg, and 15mg. Every tested dose, not just the high end. Full numbers: SURPASS-2 clinical trial.

Then came the one everyone was waiting for.

SURMOUNT-5. New England Journal of Medicine, May 2025.

751 people. 72 weeks. Maximum approved doses. Weight management, not diabetes.

Tirzepatide: 20.2% average body weight reduction.

Semaglutide: 13.7%.

The number that tells the fuller story: 31.6% of tirzepatide patients dropped 25% or more of their body weight. On semaglutide that was 16.1%. Nearly half the proportion reaching that threshold. Full data: SURMOUNT-5 clinical trial.

Real-world data backed this up.

A 2025 meta-analysis across 142,811 participants: tirzepatide 4.23% greater mean weight loss.

HIRD database, GLP-1-naive patients: tirzepatide 10.2 kg lost at 12 months. Semaglutide: 6.1 kg. The gap didn't disappear outside of trial conditions.

Cardiovascular outcomes? Different picture entirely.

Nature Medicine (2026): similar cardiovascular benefit for both drugs in elevated-risk patients. The weight loss edge is real. The heart-protection edge isn't.

Clinical Trial Weight Loss Comparison

Mounjaro vs Zepbound: Same Drug, Different Approvals

They're the same drug. Full stop.

Same molecule (tirzepatide), same manufacturer (Eli Lilly), same KwikPen device, same dose range (2.5mg to 15mg). The only thing separating them is what the FDA approved each brand to treat.

Mounjaro: type 2 diabetes.

Got FDA clearance for adults first, then pediatric patients aged 10 and older in December 2025. You start at 2.5mg weekly, bump up by 2.5mg every four weeks, top out at 15mg. That's the standard titration for both brands, for the record.

Zepbound: weight management, plus one more thing.

FDA-approved for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition. Then in 2024 the FDA added another indication: moderate-to-severe obstructive sleep apnea in adults with obesity. That second approval was notable: it expanded the prescribing rationale well beyond weight loss alone.

In the UAE, it's Mounjaro that's available through MedX Pharmacy.

Using it for weight loss without a type 2 diabetes diagnosis is off-label. Whether that's the right call for your situation is a conversation for your doctor, not an online article. A dedicated Mounjaro guide is in progress on the blog.

Ozempic vs Wegovy: Same Drug, Different Brands

Exact same pattern. Same molecule, two brands, different approved uses.

Ozempic's approvals: type 2 diabetes, cardiovascular risk reduction, chronic kidney disease risk reduction. An oral tablet version cleared in February 2026, which was genuinely new. Doses start at 0.25mg weekly, which isn't actually therapeutic, it's just the body getting used to the drug. Then 0.5mg, 1mg, max 2mg. Weight loss is not on the label. That has real implications for prescription coverage in some insurance systems. Ozempic (semaglutide) pen options at MedX Pharmacy; valid prescription required for all. Full prescribing details: Ozempic FDA prescribing information.

Wegovy got more approvals than most people realize.

Weight management for adults and kids 12+, cardiovascular risk reduction in 2024, MASH (metabolic dysfunction-associated steatohepatitis) in August 2025, and a high-dose 7.2mg version in March 2026. An oral Wegovy pill cleared December 2025. Top dose for weight management is 2.4mg weekly. An Ozempic guide is in progress on the blog.

Where Does Saxenda Fit In? Ozempic vs Saxenda

Saxenda is older and less effective. That's the honest summary.

Liraglutide. FDA-approved for weight management in 2014.

Same general receptor target as semaglutide (GLP-1 only). Predates the newer drugs by nearly a decade.

Two practical problems.

First: it's daily. Every other drug in this article is weekly.

For a lot of patients that's not a minor scheduling difference. It's a real adherence barrier. Second: the numbers from the SCALE trials were roughly 7.4% weight loss over 56 weeks. Against semaglutide's 15% and tirzepatide's 20.2%, that gap is genuinely hard to argue past when you're choosing between available options.

Still prescribed in specific cases.

Contraindications to the newer agents, step therapy, situations where a doctor has a specific clinical reason for it. MedX Pharmacy doesn't stock it.

Side Effects Compared: Which GLP-1 Has Fewer Side Effects?

Neither wins here. That's not a hedge. The profiles are genuinely close.

Both carry an FDA boxed warning for thyroid C-cell tumors from rodent studies. Whether that's relevant in humans is still an open question, but it's serious enough to land on every label.

And then there's the nausea.

Both drugs produce it, usually in the first few weeks, usually tied to dose increases, usually easing off as the body adjusts. Rates across both: nausea in 12-20% of patients, diarrhea in 8-17%, vomiting in 5-9%. You're not going to find a clean winner in those numbers.

The split, such as it is, goes like this.

Tirzepatide's pooled GI adverse event rate from the SURPASS trials climbed with dose: 39% at 5mg, 46% at 10mg, 49% at 15mg. On semaglutide, nausea runs 15-20% and constipation (5-6%) shows up more often than it does with tirzepatide. Real differences, not dramatic enough to call one drug clearly easier to stomach than the other.

Side Effects Comparison

Serious adverse effects: rare, shared across all three.

Pancreatitis. Gallbladder disease. Kidney injury.

Don't wait on any of those. Immediate medical attention.

Contraindications are the same regardless of brand.

Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). Serious hypersensitivity reactions. Type 1 diabetes. If any of those apply, the whole GLP-1 drug class is off the table.

Two newer safety developments.

Tirzepatide dosing errors: now the top adverse event in the FDA's FAERS database. Up 8-fold between 2022 and 2024. That's a device handling issue, not a pharmacology issue. Worth knowing before you start injecting.

Semaglutide: the European Medicines Agency added non-arteritic anterior ischemic optic neuropathy (NAION) to the label in 2025 as a very rare risk.

UAE Availability and Pricing Overview

MedX Pharmacy stocks Mounjaro and Ozempic. That's it for currently available GLP-1 options through MedX.

Wegovy, Zepbound, and Saxenda: not currently available.

Pricing at MedX: Mounjaro KwikPen is AED 1,734 regardless of dose (2.5mg through 15mg, same price across the range). Ozempic 0.25mg and 0.5mg pre-filled pens are AED 743.50 each; the 1mg pen is AED 1,146. Current product list at the diabetes and weight management medications page. All prescription medications require a valid prescription from a licensed healthcare provider.

One thing on the horizon worth watching.

Semaglutide patents: expiring in India, Canada, China, Brazil, Turkey starting in 2026.

Tirzepatide patents: 2036 to 2041.

Whether generic semaglutide reaches UAE shelves anytime soon is an open question. The patent timeline is just the starting point.

How to Choose the Right GLP-1 for You

Five drugs. No universal right answer.

Here's the framework worth discussing with your doctor.

Diagnosis first.

Type 2 diabetes: Ozempic and Mounjaro are both FDA-approved. Weight management without a diabetes diagnosis: Wegovy and Zepbound are the on-label options.

Using Ozempic or Mounjaro for weight loss alone is off-label. That matters for how the prescription gets written and whether your insurer covers it.

Injection schedule: Four of the five are weekly. Saxenda is daily.

For most people the weekly drugs are easier to stick with. Adherence is a bigger driver of real-world outcomes than the drug choice itself.

What's available to you: MedX Pharmacy carries Ozempic (0.25mg, 0.5mg, 1mg) and Mounjaro (2.5mg through 15mg). Wegovy, Zepbound, and Saxenda aren't currently stocked.

Cost: Mounjaro KwikPen is AED 1,734 at MedX across all doses. Ozempic 0.25mg and 0.5mg pens are AED 743.50; the 1mg pen is AED 1,146.

Your doctor's read of your full medical picture outweighs all of the above.

Don't switch between GLP-1 medications without supervision.

Frequently Asked Questions About GLP-1 Medications

Which is better, tirzepatide or semaglutide?

On weight loss? Tirzepatide.

SURMOUNT-5: 20.2% vs 13.7% average body weight reduction.

31.6% vs 16.1% reaching the 25%-loss threshold.

SURPASS-2 showed the same story on HbA1c in diabetes patients.

On approved indications, though, semaglutide leads. Cardiovascular risk reduction, MASH clearance, things tirzepatide hasn't acquired yet. Some patients also respond better to one than the other regardless of what trial averages say. Your doctor's judgment on your specific profile outweighs either result.

Which GLP-1 medication has fewer side effects?

Honestly? Neither.

The GI profiles are close enough that this shouldn't be the deciding factor. Both cause nausea, diarrhea, vomiting at similar rates early on. Both ease over the first weeks. Neither is clearly safer than the other.

Can I switch from semaglutide to tirzepatide?

Yes, under medical supervision.

No washout period is typically required. Both are weekly subcutaneous injections with similar pharmacokinetics.

Dose titration restarts at the lowest dose. You don't carry over where you left off.

Both require a valid prescription, so any switch means a new script.

What is the difference between Mounjaro and Zepbound?

The box. That's the difference.

Same tirzepatide molecule, same Eli Lilly pen, same dosing schedule. Mounjaro is the type 2 diabetes label; Zepbound is the weight management and sleep apnea label. If you're in the UAE, you're getting Mounjaro regardless of which indication applies to you.

How much weight can you lose on GLP-1 medications?

Depends entirely on which drug, which dose, and who's taking it.

Trial figures: tirzepatide (Zepbound) up to 20.2% over 72 weeks in SURMOUNT-1.

Semaglutide (Wegovy): roughly 15% over 68 weeks in STEP 1.

Liraglutide (Saxenda): about 7.4% over 56 weeks in SCALE.

Those are controlled trial conditions with close supervision, structured diet protocols, regular check-ins. Real-world outcomes are messier. Some people do better. Many do worse.

Do I need a prescription to buy Ozempic or Mounjaro in the UAE?

Yes. Always.

Both are prescription-only in the UAE. No licensed pharmacy can legally dispense either without a valid prescription from a licensed healthcare provider. MedX Pharmacy verifies prescriptions before dispensing. That's a legal requirement, not a policy choice.

Explore GLP-1 Options at MedX Pharmacy

MedX Pharmacy stocks tirzepatide and semaglutide options for patients across the UAE. View all Mounjaro products or view all Ozempic products on the website. Bring the product page to your appointment. It can speed up the prescription conversation.

All prescription medications require a valid prescription from a licensed healthcare provider.

MedX Pharmacy maintains cold chain delivery for injectable medications across the UAE, covering Dubai, Abu Dhabi, and Sharjah.

Conclusion

Tirzepatide leads on weight loss. Semaglutide leads on FDA-approved indications.

Neither is universally better.

Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist that beat semaglutide in every major head-to-head trial on weight reduction and HbA1c lowering, with the largest gaps appearing at maximum doses over long treatment periods, the conditions that matter most for real-world prescribing decisions.

Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist with a broader regulatory footprint: cardiovascular risk reduction, MASH, and more approval milestones in the pipeline. Side effects between the two are comparable. Individual responses vary.

The most useful next step is a direct conversation with your healthcare provider.

You can review available diabetes and weight management medications at MedX Pharmacy for dosage options and current availability. All prescription medications require a valid prescription from a licensed healthcare provider.

Medical Disclaimer: This article is for informational purposes only and doesn't constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. The information presented is based on publicly available clinical data and prescribing information current at the time of writing. MedX Pharmacy is a licensed pharmacy; all prescription medications require a valid prescription from a licensed healthcare provider.